Behavioral Health

Schizophrenia: diagnosis and antipsychotic selection

Clinical Overview and When to Suspect Schizophrenia

— Core symptoms: delusions, hallucinations, disorganized speech, grossly disorganized/catatonic behavior, negative symptoms (avolition, alogia, anhedonia, flat affect, asociality)

— At least one of the two must be delusions, hallucinations, or disorganized speech

— Lifetime prevalence ~0.7%; men present late teens–mid 20s, women late 20s–early 30s with a second peak after 40

— ~50% have a comorbid substance use disorder (often cannabis, nicotine, alcohol); ~5% lifetime suicide rate

— Young adult brought in by family for social withdrawal, declining school/work performance, odd beliefs, suspiciousness, or self-neglect

— New-onset auditory hallucinations without delirium, fever, or toxidrome

— Patient with prior diagnosis presenting with medication nonadherence, relapse, or new metabolic/movement side effects

— Prodromal (attenuated symptoms, functional decline) → active (frank psychosis) → residual (negative symptoms dominate)

— Earlier intervention shortens duration of untreated psychosis (DUP), the strongest modifiable prognostic factor

Board pearl: If psychotic symptoms last <1 month → brief psychotic disorder, 1–6 months → schizophreniform, ≥6 months → schizophrenia. This timeline question is the single highest-yield distinction on the exam.

Definition (DSM-5-TR): Chronic psychotic disorder requiring ≥2 of 5 core symptoms for ≥1 month (active phase), with continuous signs of disturbance for ≥6 months total, and functional decline in work, relationships, or self-care.

Epidemiology highlights for Step 3:

When to suspect in an ambulatory or ED encounter:

Course framework:

Prognosis pearls: Better outcomes with female sex, late onset, acute onset, mood symptoms, good premorbid functioning, and family support. Worse outcomes with insidious onset, prominent negative symptoms, and substance use.

Presentation Patterns and Key History

— Delusions: persecutory most common; also referential, grandiose, somatic, erotomanic, thought insertion/withdrawal/broadcasting

— Hallucinations: auditory > visual; commanding or commenting voices classic; visual hallucinations should prompt workup for delirium, substance use, or neurologic disease

— Disorganized speech: loose associations, tangentiality, word salad, neologisms

— 5 A's: anhedonia, avolition, alogia, asociality, affective flattening

— Onset, duration, and 6-month rule for prodromal + active + residual symptoms

— Mood episodes: if mood symptoms are present for a majority of the illness → schizoaffective disorder

— Substance use: cannabis, methamphetamine, cocaine, hallucinogens, PCP, synthetic cathinones

— Medication history: corticosteroids, levodopa, anticholinergics, interferon

— Medical: seizure disorder, TBI, autoimmune (anti-NMDA receptor encephalitis), HIV, syphilis, thyroid disease

— Family history: schizophrenia in first-degree relative confers ~10% risk

— Suicide/violence risk, command hallucinations, access to weapons

Key distinction: Schizoaffective disorder requires psychotic symptoms for ≥2 weeks in the absence of a mood episode, plus mood episodes present for the majority of the total illness. If mood symptoms are present only during psychosis → schizophrenia with mood features, not schizoaffective. This is a recurrent vignette trap.

Positive symptoms (added experiences, respond best to antipsychotics):

Negative symptoms (subtractions, drive most disability, respond poorly to typical antipsychotics):

Cognitive symptoms: impaired working memory, attention, processing speed — often the strongest predictor of vocational outcome

High-yield history elements to obtain:

Functional history (Step 3 emphasis): ability to maintain employment, housing stability, ADLs/IADLs, social supports, insight, adherence to prior treatment

Physical Exam Findings and Baseline Assessment

— Appearance/behavior: eye contact, cooperation, abnormal movements

— Speech: rate, rhythm, prosody; pressured speech suggests mania

— Mood/affect: flat, blunted, inappropriate, or labile

— Thought process: linear vs. tangential, circumstantial, loose, blocked

— Thought content: delusions, suicidal/homicidal ideation, obsessions

— Perception: hallucinations in any modality

— Cognition: orientation, attention, memory — disorientation suggests delirium, not schizophrenia

— Insight/judgment: typically poor in active illness

— Baseline movement assessment using AIMS (Abnormal Involuntary Movement Scale) to detect preexisting dyskinesia

— Gait, tremor, rigidity, cogwheeling (baseline for later EPS comparison)

— Weight, height, BMI, waist circumference, BP, HR — antipsychotics cause metabolic syndrome

— Fever + rigidity + autonomic instability + altered mental status on antipsychotic = neuroleptic malignant syndrome (NMS) until proven otherwise

— Fever, focal neuro deficits, nuchal rigidity, papilledema, abnormal pupils, fluctuating consciousness, age >40 with first psychotic episode

Board pearl: First-episode psychosis in a patient >40 years old, or with visual/olfactory hallucinations, focal findings, or rapid cognitive decline demands a medical workup (imaging, EEG, autoimmune panel) before assigning a primary psychiatric diagnosis. Anti-NMDA receptor encephalitis classically presents with psychosis, autonomic instability, seizures, and orofacial dyskinesias in a young woman.

General appearance: poor grooming, inappropriate dress, psychomotor agitation or retardation, catatonic features (waxy flexibility, mutism, posturing, echolalia, echopraxia)

Mental status exam (MSE) — the "physical exam" of psychiatry:

Neurologic exam — must be documented before starting antipsychotics:

Vitals and metabolic baseline:

Red flags suggesting secondary cause:

Diagnostic Workup — Initial Labs, Imaging, and Baseline Metabolic Panel

— CBC, CMP (electrolytes, glucose, BUN/Cr, LFTs)

— TSH (hyper- or hypothyroidism can mimic psychiatric illness)

— Fasting lipid panel and fasting glucose or HbA1c (metabolic baseline before antipsychotic exposure)

— Urine toxicology (cannabis, amphetamines, cocaine, PCP)

— Urinalysis and pregnancy test in women of reproductive age

— HIV, RPR/syphilis testing in appropriate risk groups

— Vitamin B12, folate if cognitive symptoms or malnutrition

— Ceruloplasmin if age <40 with movement abnormalities (rule out Wilson disease)

— Baseline QTc; particular concern with ziprasidone, IV haloperidol, thioridazine, pimozide, iloperidone

— Repeat after dose escalation or addition of QT-prolonging agents

— Indicated for first-episode psychosis with atypical features: age >40, focal neuro signs, abrupt onset, cognitive decline, history of head injury, or treatment-resistant course

— Not required for every patient but commonly ordered in first episode

Step 3 management: Before writing for an antipsychotic, document weight/BMI, waist circumference, BP, fasting glucose or A1c, lipid panel, and ECG with QTc. These are the metrics you will monitor at 12 weeks and then annually — and they are commonly tested as both clinical and quality-measure items.

Schizophrenia is a clinical diagnosis — labs and imaging are used to exclude secondary causes and establish baselines before initiating antipsychotics

Recommended baseline studies for first-episode psychosis:

ECG before initiating most antipsychotics:

Neuroimaging (MRI preferred over CT):

EEG: if temporal lobe epilepsy, ictal psychosis, or NMDA receptor encephalitis is suspected

Lumbar puncture and autoimmune encephalitis panel: if fever, seizures, dyskinesias, or rapid progression

Diagnostic Workup — Advanced and Confirmatory Studies

— A. ≥2 of 5 symptoms for ≥1 month (delusions, hallucinations, disorganized speech, disorganized/catatonic behavior, negative symptoms); at least one must be delusions, hallucinations, or disorganized speech

— B. Functional decline in work, relationships, or self-care

— C. Continuous signs ≥6 months, including ≥1 month of active-phase symptoms

— D. Schizoaffective and mood disorder with psychotic features excluded

— E. Not attributable to substance or medical condition

— F. If autism spectrum or childhood communication disorder, prominent delusions or hallucinations required ≥1 month

— PANSS (Positive and Negative Syndrome Scale)

— BPRS (Brief Psychiatric Rating Scale)

— AIMS for tardive dyskinesia surveillance every 6 months (typicals) or 12 months (atypicals)

— C-SSRS (Columbia Suicide Severity Rating Scale)

— Anti-NMDA receptor antibodies (serum and CSF) — young patient with psychosis, seizures, autonomic instability, orofacial dyskinesia

— Anti-thyroid antibodies if Hashimoto encephalopathy suspected

— Heavy metals, porphyrins in atypical presentations

— Genetic testing: 22q11.2 deletion (velocardiofacial syndrome) increases schizophrenia risk ~25-fold; consider in dysmorphic features, cardiac defects, learning disability

Board pearl: Schizophrenia has no confirmatory lab or imaging finding. If a stem offers a "definitive test," it is wrong. The diagnosis hinges on the 6-month duration criterion plus exclusion of mood, substance, and medical causes. Watch for the anti-NMDA encephalitis vignette — young woman, ovarian teratoma, psychosis, dyskinesias — which is a curable mimic.

DSM-5-TR criteria (memorize):

Standardized rating scales (useful for monitoring, not diagnosis):

Specialized testing when clinically indicated:

Neurocognitive testing: useful for documenting cognitive impairment and guiding rehabilitation, not for diagnosis

Risk Stratification and First-Line Management Logic

— Danger to self or others, inability to care for self, command hallucinations to harm → involuntary hospitalization under state civil commitment statute

— Agitation without imminent danger → de-escalation, voluntary admission or intensive outpatient

— Stable, supported, insight intact → outpatient initiation with close follow-up

— Coordinated Specialty Care (CSC) programs (e.g., NAVIGATE, OnTrackNY) are evidence-based: combine low-dose antipsychotic + family psychoeducation + supported employment/education + case management

— Lower antipsychotic doses are typically needed in FEP; patients are more sensitive to both efficacy and EPS

— First-line: any second-generation antipsychotic (SGA) except clozapine and olanzapine (reserved due to side-effect profiles)

— Avoid olanzapine in FEP due to metabolic burden in treatment-naive patients

— Choose based on side-effect profile, comorbidities, and prior response, not efficacy (most SGAs are similar in efficacy except clozapine)

— Verbal de-escalation first

— PO if cooperative: olanzapine ODT, risperidone solution, or haloperidol + lorazepam

— IM if refusing or severe: olanzapine IM, ziprasidone IM, or haloperidol + lorazepam + diphenhydramine ("B-52")

— Avoid IM olanzapine with IM benzodiazepine (respiratory depression, hypotension)

Step 3 management: After two adequate trials of different antipsychotics (at least one SGA), the patient meets criteria for treatment-resistant schizophrenia → initiate clozapine. Do not wait for a third or fourth trial; delaying clozapine is the most commonly tested management error.

Acute safety triage (first decision point):

First-episode psychosis (FEP) framework:

Antipsychotic selection logic (Step 3 favorite):

Acute agitation algorithm:

Adequate trial definition: 2–6 weeks at therapeutic dose before declaring failure

Pharmacotherapy — Antipsychotic Classes and Selection

— Risperidone: effective, but highest prolactin elevation (gynecomastia, galactorrhea, amenorrhea, sexual dysfunction); modest weight gain; EPS at higher doses

— Olanzapine: highly effective but worst metabolic profile (weight gain, dyslipidemia, diabetes); reserve for refractory cases or where weight gain acceptable

— Quetiapine: sedating, low EPS, useful with insomnia or in Parkinson disease; metabolic effects moderate

— Aripiprazole: partial D2 agonist; weight- and prolactin-neutral; can cause akathisia and activation; good for metabolic concerns

— Ziprasidone: weight-neutral, prolongs QTc, must be taken with ≥500 kcal meal for absorption

— Lurasidone: weight- and lipid-neutral; must be taken with ≥350 kcal meal; akathisia common

— Brexpiprazole, cariprazine: newer partial agonists, favorable metabolic profile

— Paliperidone: active metabolite of risperidone; renally cleared

— High potency (haloperidol, fluphenazine): high EPS, low metabolic/anticholinergic

— Low potency (chlorpromazine, thioridazine): low EPS, high anticholinergic, sedation, orthostasis, QT prolongation

— Treatment-resistant schizophrenia (failure of 2 adequate trials)

— Persistent suicidality in schizophrenia (FDA indication)

— Tardive dyskinesia unresponsive to switching

Board pearl: Match the drug to the patient: diabetic or obese → aripiprazole, lurasidone, or ziprasidone; young woman concerned about prolactin → aripiprazole; patient with insomnia → quetiapine; patient with poor adherence → long-acting injectable (LAI).

Second-generation (atypical) antipsychotics — first-line:

First-generation (typical) antipsychotics — second-line:

Clozapine — reserved for:

Mechanism summary: All antipsychotics block D2 receptors in mesolimbic pathway; atypicals also block 5-HT2A, reducing EPS risk

Long-Acting Injectables, Clozapine, and Adjuncts

— Indicated for nonadherence, frequent relapse, or patient preference; do not require treatment resistance

— Risperidone microspheres (q2 weeks), paliperidone palmitate (monthly, q3-month, q6-month), aripiprazole monohydrate or lauroxil (monthly), olanzapine pamoate (requires post-injection monitoring for delirium/sedation syndrome), haloperidol decanoate, fluphenazine decanoate

— Establish tolerability with oral form first, then transition

— Initiation: start 12.5 mg, titrate slowly to 300–450 mg/day

— REMS program required; monitor ANC weekly × 6 months, then biweekly × 6 months, then monthly

— Severe neutropenia (ANC <500): discontinue

— Adverse effects: agranulocytosis, myocarditis (first 4–8 weeks — check troponin, CRP, BNP if symptoms), seizures (dose-dependent), severe constipation/ileus (a leading cause of clozapine-related death), sialorrhea, weight gain, diabetes, orthostasis, metabolic syndrome

— Smoking cessation increases clozapine levels (1A2 induction lost) — reduce dose ~30%

— Acute dystonia: IM/IV benztropine or diphenhydramine

— Akathisia: reduce dose, add propranolol or low-dose benzodiazepine

— Parkinsonism: reduce dose, switch to lower-EPS agent, or add benztropine (avoid in elderly)

— Tardive dyskinesia: stop offending agent if possible; VMAT2 inhibitors — valbenazine or deutetrabenazine

CCS pearl: When ordering clozapine on a CCS case, sequence: baseline CBC with ANC, ECG, troponin/CRP, lipids, A1c → start 12.5 mg → weekly ANC → titrate over 2 weeks → reassess at 6 weeks.

Long-acting injectable (LAI) antipsychotics — underused, high-yield:

Clozapine — uniquely effective, uniquely risky:

EPS management:

Adjuncts: lithium or valproate for affective/aggressive features; SSRIs for comorbid depression; avoid anticholinergics in elderly

Special Populations — Elderly and Renal/Hepatic Impairment

— Boxed warning: all antipsychotics carry increased mortality risk (stroke, sudden cardiac death) in elderly patients with dementia-related psychosis — use only when behavioral interventions fail and symptoms cause significant distress or danger

— Start low, go slow: typically 25–50% of standard adult dose

— Avoid anticholinergic agents (chlorpromazine, low-potency typicals, benztropine) — delirium, falls, urinary retention, cognitive worsening

— Falls and orthostasis: prefer agents with less alpha-1 blockade

— Pimavanserin is the only FDA-approved agent for Parkinson disease psychosis (selective 5-HT2A inverse agonist, no D2 activity); quetiapine and clozapine are alternatives

— Paliperidone is renally cleared — reduce dose with CrCl <80, avoid <10

— Risperidone active metabolite (paliperidone) accumulates — reduce dose

— Aripiprazole, olanzapine, quetiapine primarily hepatic — generally safer in CKD

— Most antipsychotics are hepatically metabolized (CYP3A4, 2D6)

— Paliperidone preferred when hepatic function is compromised (renal clearance)

— Avoid chlorpromazine (cholestatic hepatitis); monitor LFTs with quetiapine, olanzapine, clozapine

— CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) raise risperidone, aripiprazole levels

— CYP3A4 inducers (carbamazepine, rifampin, phenytoin) lower aripiprazole, quetiapine, lurasidone — may precipitate relapse

— Smoking induces CYP1A2, lowers olanzapine and clozapine levels

Step 3 management: In a nursing home resident with dementia and agitation, first-line is nonpharmacologic (environmental modification, address pain/infection/constipation). If pharmacologic therapy is necessary, document the indication, obtain consent regarding the boxed warning, use the lowest effective dose, and attempt taper every 3–6 months.

Geriatric considerations:

Renal impairment:

Hepatic impairment:

Polypharmacy traps:

Special Populations — Pregnancy, Pediatrics, and Comorbid Substance Use

— Untreated psychosis carries substantial risk (self-harm, poor prenatal care, neonatal complications) — do not reflexively discontinue

— Preferred agents: haloperidol, risperidone, olanzapine, quetiapine have the most reproductive safety data

— Avoid paliperidone, ziprasidone, lurasidone (limited data); avoid clozapine if possible (agranulocytosis risk to neonate, but continue if essential)

— Third trimester: neonatal extrapyramidal symptoms and withdrawal possible — coordinate delivery and NICU monitoring

— Breastfeeding: olanzapine and quetiapine have low infant exposure; clozapine and lithium generally avoided

— Use folic acid 400 mcg–1 mg in all women of reproductive age on antipsychotics

— FDA approvals for schizophrenia in adolescents (13–17): aripiprazole, olanzapine, quetiapine, risperidone, paliperidone, lurasidone

— Adolescents are more sensitive to weight gain, metabolic effects, and prolactin elevation

— Monitor growth, Tanner staging, and metabolic parameters more frequently

— Prodromal/at-risk states: CBT and family intervention; antipsychotics not first-line for attenuated symptoms alone

— Cannabis strongly associated with earlier onset and relapse — counsel on cessation

— Tobacco: ~70% smoking rate; bupropion and varenicline are safe and effective in schizophrenia (CATIE and EAGLES data) despite older concerns

— Alcohol use disorder: naltrexone or acamprosate are compatible with antipsychotics

— Opioid use disorder: buprenorphine or methadone; coordinate care

Board pearl: A pregnant patient with schizophrenia stable on an antipsychotic should generally continue the same agent at the lowest effective dose. Switching mid-pregnancy introduces relapse risk and exposes the fetus to a second drug. This is a frequently tested counseling question.

Pregnancy and lactation:

Pediatric and adolescent:

Comorbid substance use (50% of patients):

Complications and Adverse Outcomes

— Weight gain (worst: olanzapine, clozapine), dyslipidemia, new-onset type 2 diabetes, hypertension

— Monitor: weight every visit × 6 months then quarterly; fasting glucose/A1c and lipids at baseline, 12 weeks, then annually

— Treat aggressively: lifestyle, metformin can mitigate antipsychotic-induced weight gain

— Acute dystonia: hours to days (oculogyric crisis, torticollis, laryngospasm) — treat with IM benztropine or diphenhydramine

— Akathisia: days to weeks (inner restlessness, pacing) — easily mistaken for agitation; treat with dose reduction, propranolol, or benzodiazepine

— Parkinsonism: weeks to months (bradykinesia, tremor, rigidity)

— Tardive dyskinesia: months to years (orofacial choreoathetoid movements); often irreversible — VMAT2 inhibitor (valbenazine, deutetrabenazine)

— Tetrad: hyperthermia, "lead-pipe" rigidity, autonomic instability, altered mental status

— Labs: elevated CK, leukocytosis, transaminitis, myoglobinuria → AKI

— Management: stop antipsychotic, aggressive cooling, IV fluids, benzodiazepines; severe cases — dantrolene, bromocriptine, amantadine, ICU care

— Rechallenge after ≥2 weeks with a different, lower-potency agent

Key distinction: NMS = rigidity, slow onset, normal/diminished reflexes, after antipsychotic; serotonin syndrome = hyperreflexia/clonus, rapid onset, after serotonergic agent. Both have hyperthermia and altered mental status — reflex exam discriminates.

Antipsychotic-induced metabolic syndrome:

Extrapyramidal symptoms (EPS) timeline:

Neuroleptic malignant syndrome (NMS):

Cardiovascular: QT prolongation → torsades (ziprasidone, IV haloperidol, thioridazine); myocarditis (clozapine)

Hematologic: clozapine agranulocytosis

Endocrine: hyperprolactinemia → osteoporosis, sexual dysfunction

Other: seizures (clozapine, chlorpromazine), cataracts (quetiapine — annual eye exam), constipation/ileus (clozapine), VTE risk

Mortality: patients with schizophrenia die 15–20 years earlier than the general population, mostly from cardiovascular disease and suicide

When to Escalate Care — Hospitalization and Specialty Consultation

— Imminent danger to self (active suicidal ideation with plan, recent attempt)

— Imminent danger to others (homicidal ideation, command hallucinations to harm)

— Grave disability — unable to provide for food, shelter, clothing, or essential medical care

— Acute psychosis with inability to cooperate with outpatient evaluation

— First-episode psychosis without adequate outpatient support

— Severe medication side effects requiring monitoring (NMS, agranulocytosis, severe EPS)

— Initial emergency hold (typically 72 hours) for evaluation

— Extended commitment requires judicial review and clear/convincing evidence of danger or grave disability

— Document specific behaviors, statements, and clinical reasoning — not just diagnosis

— NMS: ICU for cooling, fluid resuscitation, dantrolene

— Clozapine-induced myocarditis or agranulocytosis

— Severe ileus or aspiration from clozapine

— Torsades or hemodynamic instability from QT-prolonging antipsychotic

— Catatonia: lorazepam challenge (1–2 mg IV/IM); if responsive, continue benzodiazepines; if refractory, ECT is definitive

— Neurology: atypical features, seizures, focal findings, suspected autoimmune encephalitis

— Endocrinology: refractory hyperprolactinemia or metabolic syndrome

— Cardiology: QTc >500 ms or clozapine cardiac concerns

— Substance use treatment: integrated dual-diagnosis programs

CCS pearl: On a CCS case with acute psychosis and danger to self, sequence: vital signs → safety assessment → 1:1 sitter → place involuntary hold → obtain labs/toxicology/ECG → administer antipsychotic ± benzodiazepine → admit to inpatient psychiatry. Documenting the hold is the action many examinees forget.

Indications for inpatient psychiatric admission:

Civil commitment (varies by state):

Medical ICU/medicine consultation:

Subspecialty referrals:

Key Differentials — Other Primary Psychotic and Mood Disorders

— Psychotic symptoms ≥2 weeks without prominent mood symptoms (this is the defining feature)

— Mood episodes (major depressive or manic) present for the majority of total illness duration

— Bipolar or depressive subtype

— Treat with antipsychotic + mood stabilizer or antidepressant

— Psychotic symptoms occur only during mood episodes (manic or depressive)

— Mood-congruent (grandiose during mania) or mood-incongruent

— Treat the mood episode; antipsychotic + mood stabilizer

— Severe depression with delusions (typically nihilistic, somatic, or guilt-related) or hallucinations

— Treat with antidepressant + antipsychotic or ECT (highly effective)

— ≥1 month of non-bizarre delusions, without other prominent psychotic symptoms

— Functioning otherwise preserved

— Subtypes: erotomanic, grandiose, jealous, persecutory, somatic, mixed

— Eccentric behavior, magical thinking, ideas of reference, without frank psychosis

— Cluster A personality disorder

Key distinction: The schizophrenia vs. schizoaffective vs. mood disorder with psychotic features axis is a classic Step 3 vignette. Anchor on temporal relationship of mood and psychosis: psychosis only with mood = mood disorder with psychotic features; mood usually with psychosis but with ≥2 weeks of pure psychosis = schizoaffective; mood symptoms minimal or only during active phase = schizophrenia.

Brief psychotic disorder: psychotic symptoms <1 month, full return to premorbid function; often post-stressor or postpartum

Schizophreniform disorder: psychotic symptoms 1–6 months; ~⅔ progress to schizophrenia; functional decline not required

Schizoaffective disorder:

Bipolar I disorder with psychotic features:

Major depressive disorder with psychotic features:

Delusional disorder:

Schizotypal personality disorder:

Key Differentials — Secondary and Medical Causes of Psychosis

— Stimulants (cocaine, methamphetamine, MDMA): paranoia, tactile hallucinations ("cocaine bugs")

— Cannabis, synthetic cannabinoids: paranoia, derealization

— Hallucinogens (LSD, psilocybin, PCP, ketamine): visual hallucinations, dissociation; PCP causes violent agitation, nystagmus

— Alcohol withdrawal: delirium tremens with autonomic hyperactivity, tremor, hallucinations

— Alcoholic hallucinosis: auditory hallucinations with clear sensorium during withdrawal

— Steroids, levodopa, anticholinergics, interferon, isoniazid, chloroquine

— Fluctuating consciousness, inattention, disorientation, acute onset — distinguishes from primary psychosis

— Visual hallucinations more common; auditory less so

— Workup: infection, metabolic derangement, medications, hypoxia, intracranial process

— Temporal lobe epilepsy: ictal or postictal psychosis, automatisms, déjà vu

— Huntington disease: chorea, psychiatric symptoms, family history

— Parkinson disease and Lewy body dementia: visual hallucinations, REM sleep behavior disorder

— Alzheimer disease: late-stage psychosis (often misidentification delusions)

— Multiple sclerosis, neurosyphilis, HIV-associated neurocognitive disorder, prion disease

— Autoimmune encephalitis (anti-NMDA receptor): psychosis, seizures, dyskinesias, autonomic instability — young woman with ovarian teratoma

— Brain tumor, stroke, traumatic brain injury

— Thyroid disease, Cushing syndrome, Addison disease, hypoglycemia, hyponatremia, hypercalcemia, uremia, hepatic encephalopathy

— Wilson disease (age <40, Kayser-Fleischer rings, hepatic dysfunction)

— Acute intermittent porphyria (abdominal pain, neuropathy, psychosis)

— Vitamin B12, thiamine (Wernicke), niacin (pellagra) deficiency

Board pearl: First psychotic episode >40 years old, visual/olfactory hallucinations, focal neuro signs, or rapid cognitive decline = workup secondary cause before diagnosing schizophrenia. A normal MRI does not rule out autoimmune encephalitis — send antibody panel.

Substance-induced psychotic disorder:

Delirium:

Neurologic causes:

Endocrine/metabolic:

Secondary Prevention, Discharge Planning, and Long-Term Pharmacotherapy

— First episode: continue antipsychotic for at least 1–2 years after symptom remission

— Multiple episodes or severe first episode: indefinite/lifelong maintenance

— Discontinuation increases relapse risk ~5-fold within 1 year

— Gradual taper over months, not abrupt

— Close monitoring for prodromal symptoms; reinitiate immediately if relapse signs

— Shared decision-making with documentation of risks

— Nonadherence (objective or suspected)

— History of relapse leading to hospitalization

— Patient preference

— Reduced relapse and hospitalization vs. oral agents in real-world studies

— Outpatient follow-up within 7 days (HEDIS quality measure)

— Medication reconciliation; written instructions on dose, side effects, when to call

— Naloxone/safety planning if substance use; means restriction if suicidal

— Connection to assertive community treatment (ACT) or intensive case management for high-utilization patients

— Address social determinants: housing, benefits (SSDI/SSI), transportation, food

— Statin per ASCVD risk; lower threshold given excess CV mortality

— Aggressive BP control, diabetes screening and treatment

— Smoking cessation: varenicline or NRT + behavioral support

— Annual flu vaccine; routine cancer screening (frequently missed in this population)

Step 3 management: A patient hospitalized for psychotic relapse due to nonadherence to oral risperidone should be transitioned to a long-acting injectable before discharge, with the first outpatient visit scheduled within 7 days. The 7-day follow-up benchmark is both clinical best practice and a quality metric.

Duration of antipsychotic therapy:

If discontinuation is attempted:

Long-acting injectables (LAIs) — strongly consider for:

Discharge checklist after acute hospitalization:

Cardiometabolic risk management — primary care responsibility:

Follow-Up, Monitoring Parameters, and Psychosocial Rehabilitation

— Baseline: personal/family history, weight/BMI, waist circumference, BP, fasting glucose or A1c, fasting lipids, ECG (if indicated), AIMS

— 4 weeks: weight

— 8 weeks: weight

— 12 weeks: weight, BP, fasting glucose/A1c, lipids

— Quarterly thereafter: weight, BP

— Annually: fasting glucose/A1c, lipids, AIMS (every 6 months for typicals)

— Prolactin if symptomatic (galactorrhea, amenorrhea, sexual dysfunction)

— Cognitive behavioral therapy for psychosis (CBTp): reduces positive and negative symptoms

— Family psychoeducation: reduces relapse and rehospitalization by ~50%

— Assertive community treatment (ACT): for high-utilizers

— Supported employment (IPS model): improves vocational outcomes

— Social skills training, cognitive remediation

— Coordinated specialty care for first-episode psychosis (NAVIGATE, OnTrackNY)

— Simplify regimens, LAIs, pill organizers, family involvement, digital reminders

— Address side effects proactively — the #1 cited reason for discontinuation

— Annual dental, vision, primary care; vaccinations; cancer screening per USPSTF

— Bone density if hyperprolactinemia or long-term typical antipsychotic

Board pearl: Family psychoeducation is one of the few interventions in psychiatry with relapse reduction comparable to medication. When a stem mentions high "expressed emotion" (criticism, hostility, overinvolvement) in the family, the correct answer is family-focused therapy.

Antipsychotic monitoring schedule (ADA/APA consensus):

Clozapine-specific: ANC weekly × 6 months → biweekly × 6 months → monthly indefinitely; troponin/CRP/echo if myocarditis suspected (first 4–8 weeks)

Psychosocial interventions — evidence-based, frequently underused:

Adherence strategies:

Health maintenance not to forget:

Ethical, Legal, and Patient Safety Considerations

— Diagnosis of schizophrenia does not equal incapacity — assess decision-making capacity for each specific decision

— Capacity requires: understanding the information, appreciating consequences, reasoning through options, and communicating a choice

— If incapacitated, follow state law: surrogate decision-maker, guardian, or court order

— Civil commitment for danger to self, danger to others, or grave disability

— Involuntary medication generally requires separate judicial proceeding (e.g., Rogers hearing in MA, Sell hearing if competency-related) — emergency administration permitted for imminent danger

— Document specific behaviors and clinical reasoning, not diagnosis alone

— Tarasoff duty to warn/protect: if patient makes credible threat against identifiable victim, clinician must take reasonable steps (warn victim, notify police, hospitalize)

— Mandatory reporting: child or elder abuse, certain communicable diseases

— HIPAA permits disclosure to family/caregivers when patient lacks capacity and disclosure is in patient's best interest

— Post-discharge first 30 days is highest suicide-risk period in schizophrenia

— Ensure 7-day follow-up, medication availability (no gaps), warm handoff to outpatient team, safety planning, means restriction

— Reconcile medications; clarify which agent and dose are current — discharge summaries with antipsychotic errors are a leading sentinel event

Step 3 management: A patient with schizophrenia tells you he plans to shoot his neighbor whom he believes is poisoning him. The required actions are: psychiatric hospitalization (involuntary if needed), notification of the identifiable potential victim, and notification of law enforcement — this is the Tarasoff trio.

Informed consent and capacity:

Involuntary treatment:

Confidentiality and exceptions:

Transition-of-care safety (Step 3 emphasis):

Boxed warnings to disclose: elderly dementia mortality, antidepressant-related suicidality in young adults if coprescribed, clozapine agranulocytosis/myocarditis, metabolic risks

Driving and firearms: counsel and document; varies by state reporting laws

High-Yield Associations and Rapid-Fire Clinical Facts

— Concordance: monozygotic twins ~50%, dizygotic ~15%, first-degree relative ~10%, general population ~1%

— 22q11.2 deletion (DiGeorge/velocardiofacial): ~25-fold increased risk

— Cannabis use in adolescence doubles risk in genetically vulnerable individuals

— Enlarged lateral and third ventricles, reduced hippocampal/amygdala volume, reduced gray matter

— Hypofrontality on functional imaging

— Mesolimbic hyperactivity → positive symptoms (blocked by D2 antagonists)

— Mesocortical hypoactivity → negative and cognitive symptoms

— Nigrostriatal blockade → EPS

— Tuberoinfundibular blockade → hyperprolactinemia

— Weight gain: "Most patients Quickly Crave Olanzapine" — olanzapine > clozapine > quetiapine, risperidone

— Prolactin: risperidone, paliperidone, haloperidol (high); aripiprazole, brexpiprazole (lowest)

— QT prolongation: ziprasidone, iloperidone, thioridazine, IV haloperidol

— Metabolically neutral: aripiprazole, lurasidone, ziprasidone, brexpiprazole

— With food requirement: ziprasidone (500 kcal), lurasidone (350 kcal)

Board pearl: Clozapine is the only antipsychotic shown to reduce suicide risk in schizophrenia and is FDA-approved for that indication independent of treatment resistance.

Genetics and risk:

Neuroimaging findings (not diagnostic):

Dopamine hypothesis simplified:

Antipsychotic memory aids:

Mortality drivers: cardiovascular disease (#1), suicide (~5% lifetime), accidents, substance use

Suicide risk factors in schizophrenia: young, male, high IQ/insight, recent discharge, depressive symptoms, prior attempt, substance use, command hallucinations

Schneiderian first-rank symptoms (historical, not required by DSM): thought broadcasting/insertion/withdrawal, delusions of control, running commentary auditory hallucinations

Good vs. poor prognosis: acute/late onset, mood symptoms, female, married, good premorbid function = better; insidious onset, prominent negatives, no precipitant = worse

Board Question Stem Patterns

— 23-year-old with 3 weeks of paranoid delusions and auditory hallucinations after a stressor, full recovery in 4 weeks → brief psychotic disorder

— 4 months → schizophreniform

— 8 months → schizophrenia

— 19-year-old with 7 months of social withdrawal, declining grades, paranoid delusions; urine tox negative, MRI normal. Answer: SGA other than olanzapine/clozapine (e.g., risperidone, aripiprazole) + coordinated specialty care.

— Patient failed adequate trials of risperidone and aripiprazole → clozapine with REMS enrollment and weekly ANC monitoring

— Young man on haloperidol with neck twisting hours after dose → acute dystonia → IM benztropine

— Patient on antipsychotic with fever, rigidity, AMS, elevated CK → NMS → stop drug, supportive care ± dantrolene

— Inner restlessness, pacing → akathisia → reduce dose, propranolol

— Lip-smacking after years of antipsychotic → tardive dyskinesia → VMAT2 inhibitor

— When to check fasting lipids and glucose after starting an SGA → baseline, 12 weeks, then annually

— Multiple admissions for psychotic relapse, "stops meds when I feel better" → long-acting injectable

— 26-year-old woman with psychosis, seizures, orofacial dyskinesias, autonomic instability, pelvic mass → anti-NMDA receptor encephalitis with ovarian teratoma

— Patient threatens identifiable victim → Tarasoff duty: hospitalize, warn victim, notify police

— Pregnant patient stable on antipsychotic → continue current agent at lowest effective dose

— Elderly with dementia and agitation → nonpharmacologic first; antipsychotics carry mortality boxed warning

Key distinction: When the stem highlights mood symptoms throughout most of the illness with ≥2 weeks of pure psychosis, the answer is schizoaffective disorder, not schizophrenia and not bipolar with psychotic features. Anchor on temporal overlap of mood and psychosis.

Pattern 1 — Duration distinguishes the diagnosis:

Pattern 2 — First-episode psychosis management:

Pattern 3 — Treatment-resistant schizophrenia:

Pattern 4 — Side effect pattern recognition:

Pattern 5 — Metabolic monitoring:

Pattern 6 — Adherence/LAI:

Pattern 7 — Secondary cause:

Pattern 8 — Ethics/safety:

Pattern 9 — Special population:

One-Line Recap

Schizophrenia is a clinical diagnosis requiring ≥6 months of continuous illness with ≥1 month of active psychosis plus functional decline, managed long-term with a second-generation antipsychotic chosen by side-effect profile, escalated to clozapine after two adequate trials, and supported with metabolic monitoring, psychosocial rehabilitation, and rigorous transition-of-care follow-up.

Board pearl: When in doubt on a Step 3 schizophrenia vignette, ask three questions — How long have symptoms lasted? Are mood symptoms driving the picture? Has the patient failed two adequate antipsychotic trials? Those three answers steer nearly every diagnostic and management decision the exam will ask of you.

Diagnosis recap: ≥2 of 5 core symptoms (delusions, hallucinations, disorganized speech, disorganized/catatonic behavior, negative symptoms) — at least one must be delusions, hallucinations, or disorganized speech — for ≥1 month active + ≥6 months total, with mood and substance/medical causes excluded.

First-line treatment recap: Any SGA except clozapine and olanzapine for first episode; match drug to patient (metabolic-neutral aripiprazole or lurasidone for obesity/diabetes; prolactin-neutral aripiprazole for young women; sedating quetiapine for insomnia; LAI for nonadherence). Adequate trial = 2–6 weeks at therapeutic dose; after two failed adequate trials → clozapine.

Monitoring recap: Baseline weight/BMI, waist circumference, BP, fasting glucose/A1c, lipids, ECG, AIMS; reassess weight at 4/8/12 weeks, full metabolic panel at 12 weeks and annually, AIMS every 6–12 months. Clozapine adds weekly → biweekly → monthly ANC plus monitoring for myocarditis, ileus, and seizures.

Safety/transitions recap: Highest relapse and suicide risk window is the first 30 days post-discharge — schedule outpatient follow-up within 7 days, confirm medication access, engage family, deploy ACT or coordinated specialty care for high-risk patients, and document Tarasoff actions when threats are credible and victim is identifiable. Always assess capacity individually and remember that the boxed warning for antipsychotic use in elderly dementia patients mandates a documented risk-benefit discussion.